27 Résultats pour

Lancet Oncology

Format pdf - Page 1/1 (Temps écoulé: 0.3377)



1 Nivolumab In Patients With Advanced Gastric Or Gastro ...
www.thelancet.com Vol 390 December 2, 2017 2461 Articles Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,



2 Le Syndrome D’activation Macrophagique Oouu Syndrome ...
PRONOSTIC des SAM de l’adulte 50% des patients passent en réanimation (Riviere et al. Am J Med 2014, Ramos-Casals et al Lancet 2014) 354 patients



3 Olaratumab And Doxorubicin Versus Doxorubicin Alone For ...
Articles 490 www.thelancet.com Vol 388 July 30, 2016 Procedures In the phase 1b part of the study, patients received olaratumab (15 mg/kg) intravenously on day 1 and day 8



4 Protocol: Carboplatin/paclitaxel - Mid-western Cancer Centre
Department of Medical Oncology Chemotherapy Protocols 3rd Edition 57 Protocol: Carboplatin Indications: Ovarian Cancer – Advanced, Recurrent



5 日本乳癌学会認定医・専門医更新のための業績基準
日本乳癌学会認定医・専門医更新のための業績基準. i. 学 会 発 表. a. 国内学会. 1) 日本乳癌学会. 2) 日本医学会総会



6 Basic Infection Control And Prevention Plan For Outpatient ...
Basic Infection Control . And Prevention Plan for. Outpatient. Oncology Settings. National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion



7 Nccn Guidelines For Bone Cancer V.1.2018 ... - Oncology
NCCN Guidelines for Bone Cancer V.1.2018 –Follow-Up on 08/14/17 Winkler, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on



8 New Immunotherapies: Management Of Immune Related Adverse ...
New Immunotherapies: Management of Immune Related Adverse Events Dr. Margaret Smith . General Practitioner in Oncology



9 Allogeneic Transplant Conditioning Regimens: Does The ...
Allogeneic Transplant Conditioning regimens: does the choice matter? Steven Devine MD The Ohio State University. Comprehensive Cancer Center



10 Diagnosis And Follow-up Of Multiple Myeloma And Related ...
Learning Objectives • Compare traditional myeloma testing methods with current recommended protocols and describe how kappa & lambda free light chain analysis plays a key role.

Recherches Associées :
Pages : 1